ArticlePharmacoEconomics - open2022

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia.

Ahmed Alghamdi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.